Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmace...

FDA Recall #D-0562-2024 — Class II — May 17, 2024

Recall #D-0562-2024 Date: May 17, 2024 Classification: Class II Status: Completed

Product Description

Duloxetine Delayed-Release Capsules, USP, 60mg, 90-count bottle, Rx Only, Mfr. by: Towa Pharmaceutical Europe, S.L. Martorelles, (Barcelona), Spain, Dist. by: Breckenridge Pharmaceuticals, Inc., Berkeley Heights, NJ 07922. NDC 51991-748-90

Reason for Recall

CGMP Deviations: Presence of N-nitroso-duloxetine impurity above FDA recommended interim limit

Recalling Firm

Breckenridge Pharmaceutical, Inc — Berlin, CT

Classification

Class II — May cause temporary or medically reversible adverse health consequences.

Product Type

Drugs

Product Quantity

165,678, 90-count bottles

Distribution

Nationwide in the USA

Code Information

Lot #: 230035C, Exp. date 11/30/2025; 230101C, Exp. date 12/31/2025

Status

Completed

Voluntary / Mandated

Voluntary: Firm initiated